TOP TEN perturbations for 38439_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38439_at
Selected probe(set): 200759_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38439_at (200759_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.8317938Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.8178406Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):1.7359657Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
tunicamycin study 1 / vehicle (DMSO) treated B-cell-derived EBV-transformed lymphoblastoid cell sample
Relative Expression (log2-ratio):1.6155472Number of Samples:60 / 60
| Experimental | tunicamycin study 1 |
| B-cell-derived EBV-transformed lymphoblastoid cells (derived from Coriell cell repository) from unrelated individuals (grandparents in the HapMap CEPH-Utah pedigrees) were treated with 4 ug/ml tunicamycin for 8 hours. Tunicamycin is a mixture of homologous nucleoside antibiotics inhibiting polyprenol-P HexNAc-1-P family of enzymes. Tunicamycin blocks N-linked glycosylation (N-glycans) induce unfolded protein response (UPR) leading to accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER). ATC code:--- | |
| Control | vehicle (DMSO) treated B-cell-derived EBV-transformed lymphoblastoid cell sample |
| B-cell-derived EBV-transformed lymphoblastoid cells (derived from Coriell cell repository) from unrelated individuals (grandparents in the HapMap CEPH-Utah pedigrees) treated with vehicle DMSO for 8 hours. |
4-hydroxytamoxifen study 1 (empty vector) / FoxO3 H212R overexpr. study 1
Relative Expression (log2-ratio):-1.6133556Number of Samples:3 / 3
| Experimental | 4-hydroxytamoxifen study 1 (empty vector) |
| Human umbilical vein endothelial cells (HUVECs) transfected with empty retroviral pBabe puro vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- | |
| Control | FoxO3 H212R overexpr. study 1 |
| Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.6080856Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
thapsigargin (50uM; 6h); salubrinal (40uM; 24h) study 1 / vehicle (DMSO) treated LCL cell sample (24h)
Relative Expression (log2-ratio):1.6049824Number of Samples:2 / 2
| Experimental | thapsigargin (50uM; 6h); salubrinal (40uM; 24h) study 1 |
| Lymphoblastoid cell line (LCL) derived from peripheral blood mononuclear cells infected with EBV (strain B95-8) was treated with 50μM thapsigargin and 40μM salubrinal for 6 h. Then, thapsigargin was washed out and cells were cultured in presence of 40μM salubrinal for additional 18 h. ATC code:--- | |
| Control | vehicle (DMSO) treated LCL cell sample (24h) |
| Lymphoblastoid cell line (LCL) derived from peripheral blood mononuclear cells infected with EBV (strain B95-8) was treated with DMSO for 24 h. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-1.6023903Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-1.5835676Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):1.5763769Number of Samples:3 / 4
| Experimental | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |